Joaquim Bellmunt
Beth Israel Deaconess Medical Center
725 Papers
5.2K Citations
Joaquim Bellmunt is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Medicine & Bladder cancer. The author has an hindex of 82, co-authored 660 publications. Previous affiliations of Joaquim Bellmunt include University of Cambridge & Brigham and Women's Hospital.
Chat about Author
Papers
The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients
TL;DR: In this article, the authors present a risk analysis of VEGF inhibitors in patients with advanced renal cell carcinoma (RCC) and show that they are associated with a small but real risk of potentially life threatening and contrasting toxicities of thrombosis (both venous and arterial) and bleeding.
Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma
TL;DR: Clinical benefit of atezolizumab occurred in patients with compromised renal function or MVH UC tumors and safety was similar, in most patient subgroups with varying levels of kidney functioning or less common types of tumor tissue histology.
Non-muscle-invasive micropapillary bladder cancer has a distinct lncRNA profile associated with unfavorable prognosis
Joep J. de Jong,Begoña P. Valderrama,J. Perera,Nuria Juanpere,Paloma Cejas,Henry W. Long,M. Mar Albà,Ewan A. Gibb,Joaquim Bellmunt +8 more
TL;DR: In this paper , a single-sample genomic signature was trained using lasso-penalized logistic regression to classify micropapillary-like gene-expression, as characterised by lncRNA clustering.
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Marco Bandini,Alberto Briganti,Elizabeth R. Plimack,Günter Niegisch,Evan Y. Yu,Aristotelis Bamias,Neeraj Agarwal,Srikala S. Sridhar,Cora N. Sternberg,Ulka N. Vaishampayan,Christine Theodore,Jonathan E. Rosenberg,Joaquim Bellmunt,Matthew D. Galsky,Francesco Montorsi,Andrea Necchi +15 more
TL;DR: A prognostic model predicting 1-yr survival free from recurrence of bladder cancer after radical cystectomy, with or without standard chemotherapy, could provide an improvement to the quality of phase 2 clinical trial designs and interpretation of their results.
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries
Camillo Porta,Antonin Levy,Robert E. Hawkins,Daniel Castellano,Joaquim Bellmunt,Paul Nathan,Ray McDermott,John Wagstaff,Paul Donnellan,John McCaffrey,Francis Vekeman,Maureen P. Neary,Jose Diaz,Faisal Mehmud,Mei Sheng Duh +14 more
TL;DR: A study of advanced RCC patients treated with sunitinib in Europe found a significant relationship between AEs and dose intensity, and correlations between dose intensity and shorter survival, and between dose discontinuation and short survival.